Our bioadhesive delivery system (BDS) is a unique drug delivery technology that facilitates binding to mucosal surfaces upon administration, and allows release of the active drug in a controlled and sustained manner until the BDS formulation is discharged upon normal cell turnover. This occurs every three to five days for the vaginal epithelium, and up to every 24 hours for the oral mucosa.
The key BDS ingredient is polycarbophil, which is a non-immunogenic, hypo-allergenic, bioadhesive polymer. Polycarbophil bonds to the cells of the body’s mucosal surfaces upon administration. This happens because polycarbophil mimics negatively charged mucin, the glycoprotein component of mucus that is responsible for its attachment to underlying epithelial surfaces.
Two types of BDS formulations have been developed: gels and tablets.
We are evaluating additional clinical applications of this legacy technology, focusing on potential opportunities where the bioadhesive properties and shorter duration of the BDS align with desired product profile and unmet need.
Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.
Replens® and RepHresh® are registered trademarks of Church & Dwight Co.